The Knight Diagnostic Laboratories have extensive experience in developing
tests for solid tumors and hematopoietic malignancies.
KDL Medical Directors are experts in diagnostic testing, with decades of clinical service experience, collaborations with researchers at Oregon Health & Sciences University and interactions with industry.
In addition to pioneering the application of broad-based tumor genotyping the Knight Diagnostic Laboratories continue to build new test offerings in support of personalized cancer care.
Molecular Diagnostic Offerings Include:
- Next generation sequencing using Illumina NextSeq 500/550 technology for solid tumor and hematologic disorders as well as inherited cancer syndromes
- CytoSure Medical Research Exome Array (1 million elements) which is exon-specific, with 4,645 medically-relevant genes
- Next-generation sequencing of tumor RNA to detect clinically informative gene fusions and splice alterations
- Karyotyping and FISH
- Tumor enrichment protocols using macrodissection and microdissection (laser capture)
- Array CGH
- Real-time PCR assays using a variety of readouts, including high resolution melting curve analyses
- High sensitivity RNA detection assays
- Standard Sanger sequencing
- Gene methylation analyses
- Gene copy number analyses
- Pathologist-directed macrodissection for tumor enrichment
Next Generation Sequencing panels include:
KDL medical specialists are available to consult and can help you decide which Oncology tests will fit your patient's needs. Request your test today or contact Knight Diagnostic Laboratories Client Services.